Protagonist Therapeutics, Inc (PTGX): Capital Expenditures
$1.59M
Year ended 2025-12-31
$615.0K
Trailing 12 months to 2026-06-30
+26.0%
3-year compound annual growth
+27.5%
5-year compound annual growth
+14.8%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.59M | +17.3% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $1.35M | +122.5% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $609.0K | -23.4% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $795.0K | -27.8% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $1.10M | +133.8% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $471.0K | -51.3% | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $967.0K | +99.0% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $486.0K | -27.0% | 2021-03-10, From 2018-01-01 |
| 2017-12-31 | $666.0K | +91.9% | 2020-03-10, From 2017-01-01 |
| 2016-12-31 | $347.0K | -13.0% | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | $399.0K | +33.4% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $299.0K | n/a | 2017-03-07, From 2014-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $1.59M | +17.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $518.0K | -75.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $562.0K | +253.5% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $97.9K | +47.3% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $346.0K | +81.2% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $518.0K | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $79.0K | n/a |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $718.0K | -23.5% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $0 | -100.0% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗